Screener
Merit Medical Systems MMSI Single Reportable — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Merit Medical Systems in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Merit Medical Systems’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:23 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000856982-26-000025
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cost of sales other(2) | 50,063 | 40,528 |
| Selling and marketing expenses | 73,957 | 64,929 |
| General and administrative expenses | 44,253 | 42,557 |
| Research and development expenses | 22,609 | 22,478 |
| Other operating expenses(3) | (179) | 1,023 |
| Other (income) expense — net | (9,389) | 3,075 |
| Income tax expense | 12,551 | 7,811 |
| Net income | $40,995 | $30,147 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Merit Medical Systems's single reportable — research and development expense?
- Merit Medical Systems (MMSI) reported single reportable — research and development expense of $22.61M in Q1 2026.
- What does single reportable — research and development expense mean?
- This metric represents the investment in innovation, clinical trials, and the development of new medical technologies within the segment. It is a critical indicator of the company's commitment to long-term product pipeline growth and competitive differentiation. Investors monitor this to gauge the sustainability of the company's future revenue streams and technological leadership.
Ask your AI about Merit Medical Systems's single reportable — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude